![Wouter Vervecken](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Wouter Vervecken
Amministratore Delegato presso Oxyrane UK Ltd.
Profilo
Wouter Vervecken is currently the Chief Executive Officer at Oxyrane UK Ltd.
He has a background in undergraduate, graduate, and doctorate degrees from Ghent University.
Posizioni attive di Wouter Vervecken
Società | Posizione | Inizio |
---|---|---|
Oxyrane UK Ltd.
![]() Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Amministratore Delegato | - |
Formazione di Wouter Vervecken
Ghent University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Oxyrane UK Ltd.
![]() Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Wouter Vervecken